While Pfizer and Moderna hold the lead, new data from J&J, Novavax show there's 'room for everyone' in the market: analysts

With Novavax and Johnson & Johnson data now in hand, the world has efficacy numbers on at least five COVID-19 vaccine programs. That's plenty for analysts to parse—and they're busy doing not only that, but also sizing up the market as the field of top players grows.